📋 Tender Overview
Reference: 20250260
Release date: 28 August 2025
Promoter – Financial Intermediary
XELTIS BV
Location
The Netherlands
Description
The project will finance the promoter’s Research & Development (R&D)to further develop transformative vascular implants using supramolecular chemistry. The R&D investments focus on solutions for vascular access, coronary and peripheral bypass grafts, and pulmonary heart valves.
Objectives
The project focuses on the development, clinical validation, and regulatory approval of aXess, an innovative haemodialysis conduit leveraging Xeltis' proprietary Endogenous Tissue Restoration (ETR) technology, which enables the body to naturally restore functional vascular tissue. Additionally, the concerned R&D investments include clinical research, for novel therapeutic applications such as Coronary Artery Bypass Graft (XABG program), Peripheral Artery Diseases (Xpad program) and Pulmonary Valve (Xplore program).
Sector(s)
Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 38 million
Total cost (Approximate amount)
EUR 77 million
Environmental aspects
The project would not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC as research, development and innovation activities will be carried out in facilities already authorised for the same purpose. Full environmental details will nevertheless be verified to align with EU best practices.
Procurement
The EIB requires that all project contracts are procured in accordance with the applicable EU procurement legislation.
Status
Under appraisal
